A potential therapeutic strategy for diabetes and its complications in the form of co-encapsulated antioxidant nanoparticles (NanoCAPs) of ellagic acid and coenzyme Q10: Preparation and evaluation in streptozotocin induced diabetic rats

Journal of Biomedical Nanotechnology

Volumn 4, Issue 1, 2008, Pages 33-43

  Ratnam, D Venkat ^a   Chandraiah, Godugu ^a   Sonaje, Kiran ^a   Viswanad, Boomi ^a   Bhardwaj, Vivekanand ^a   Ramarao, Poduri ^a   Ravikumar, M N V ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Antioxidants; Coenzyme Q10; Diabetes; Ellagic acid; Nanoparticles; Oxidative damage

Indexed keywords

ACIDS; GLUCOSE; RATS; SUGAR (SUCROSE);

ANTIOXIDANTS; BENEFICIAL EFFECTS; DIABETES; DIABETIC RATS; DYSLIPIDEMIA; ELLAGIC ACID; LIPID PEROXIDATION; METABOLIC DISORDERS; NANO PARTICULATES; NANOCAPS; OXIDATIVE DAMAGE; PLASMA INSULIN LEVELS; STREPTOZOTOCIN; THERAPEUTIC STRATEGIES;

NANOPARTICLES;

ANTIOXIDANT; ELLAGIC ACID; INSULIN; NANOPARTICLE; UBIDECARENONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIODEGRADABILITY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DYSLIPIDEMIA; ENCAPSULATION; INSULIN BLOOD LEVEL; LIPID PEROXIDATION; LOW DRUG DOSE; MALE; MONOTHERAPY; NONHUMAN; RAT; RISK REDUCTION; STREPTOZOCIN DIABETES;

EID: 57749176217     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. K. G. M. M. Alberti and P. Z. Zimmet, Definition, diagnosis and classification of diabetes mellitus and its complications. Diabet. Med. 15, 539 (1998).
2. D. M. Nathan, Long-term complications of diabetes mellitus. New Engl. J. Med. 328, 1676 (1993).
3. DCCT Research Group, The effect of intensive therapy of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus. New Engl. J. Med. 329, 977 (1993).
4. DCCT Research Group, Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. New Engl. J. Med. 342, 381 (2000).
5. UK Prospective Diabetes Research Group, Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352, 854 (1998).
6. UK Prospective Diabetes Research Group, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352, 837 (1998).
7. I. M. Stratton, A. I. Adler, H. A. Neil, D. R. Matthews, S. E. Manley, C. A. Cull, D. Hadden, R. C. Turner, and R. R. Holman, Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. Brit. Med. J. 321, 405 (2000).
8. American Diabetes Association, Standards of medical care in diabetes. Diabetes Care 28, s4 (2006).
9. M. Brownlee, Biochemistry and molecular cell biology of diabetic complications. Nature 414, 813 (2001).
10. T. Nishikawa, D. Edelstein, and X. Du, Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404, 787 (2000).
11. J. L. Leahy, Natural history of b-cell dysfunction in NIDDM. Diabetes Care 13, 992 (1990).
12. M. Tiedge, S. Lortz, J. Drinkgern, and S. Lenzen, Relation between antioxidant enzyme gene expression and antioxidative defense status of insulin-producing cells. Diabetes 46, 1733 (1997).
13. M. Vessal, M. Hemmati, and M. Vasie, Antidiabetic effects of quercetin in streptozotocin-induced diabetic rats. Comp. Biochem. Physiol. C 135, 357 (2003).
14. O. Coskun, M. Kanter, A. Korkmaz, S. Oter, and Quercetin, A flavonoid antioxidant, prevents and protects streptozotocin-induced oxidative stress and β-cell damage in rat pancreas. Pharmacol. Res. 51, 117 (2005).
15. 10 and L-carnitine be a treatment for diabetes secondary to 3243 mutation of mtDNA. Diabetologia 39, 1485 (1996).
16. 10 on maternally inherited diabetes mellitus and deafness, and mitochondrial DNA 3243 (A to G) mutation. Diabetologia 41, 584 (1998).
17. H. Ueda, K. Kawanishi, and M. Moriyasu, Effects of ellagic acid and 2-(2,3,6-trihydroxy-4-carboxyphenyl)ellagic acid on sorbitol accumulation in vitro and in vivo. Biol. Pharm. Bull. 27, 1584 (2004).
18. 10 improves endothelial dysfunction of the brachial artery in type II diabetes mellitus. Diabetologia 45, 420 (2006).
19. 10 in heart and liver mitochondria of rats with streptozotocin-induced diabetes. Physiol. Res. 49, 411 (2000).
20. 10 on the antioxidation status the basic parameters of metabolism of fats and sugars in diabetic patients. Slovensky Lekar 12, 35 (1997).
21. B. Frei, M. C. Kim, and B. N. Ames, Ubiquinol-10 is an effective lipid soluble antioxidant at physiological concentrations. Proc. Natl. Acad. Sci. USA 87, 4879 (1990).
22. D. V. Ratnam, D. D. Ankola, V. Bhardwaj, D. K. Sahana, and M. N. V. R. Kumar, Role of antioxidants in prophylaxis and therapy: A pharmaceutical perspective. J. Control. Rel. 113, 189 (2006).
23. I. Bala, V. Bhardwaj, S. Hariharan, J. Sitterberg, U. Bakowsky, and M. N. V. R. Kumar, Design of biodegradable nanoparticles: A novel approach to encapsulating poorly soluble phytochemical ellagic acid. Nanotechnology 16, 2819 (2005).
24. I. Bala, V. Bhardwaj, S. Hariharan, and M. N. V. R. Kumar, Analytical methods for assay of ellagic acid and its solubility studies. J. Pharm. Biomed. Anal. 40, 206 (2005).
25. A. C. Whitley, G. D. Stoner, M. V. Darby, and T. Walle, Intestinal epithelial cell accumulation of the cancer preventive polyphenol ellagic acid-extensive binding to protein and DNA. Biochem. Pharmacol. 66, 907 (2003).
26. 10: Absorption, tissue uptake, metabolism and pharmacokinetics. Free Radic. Res. 40, 445 (2006).
27. 10 by derivative spectroscopy and HPLC. Talanta 70, 387 (2006).
28. H. Ohkawa, N. Ohishi, and K. Yagi, Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 95, 351 (1979).
29. D. H. Lowry, N. Y. Rosenbrough, A. L. Farr, and R. J. Randall, Protein measurement with the folin phenol reagent. J. Biol. Chem. 193, 265 (1951).
30. 10 and vitamin E alter the status of these compounds in rat tissues and mitochondria. J. Nutr. 130, 2343 (2000).
31. Y. Zhang, F. Aberg, E. L. Appelkvist, G. Dallner, and L. Ernster, Uptake of dietary coenzyme Q supplement is limited in rats. J. Nutr. 125, 446 (1995).
32. Y. Zhang, M. Turunen, and E. L. Appelkvist, Restricted uptake of dietary coenzyme Q is in contrast to the unrestricted uptake of α-tocopherol into rat organs and cells. J. Nutr. 126, 2089 (1996).
33. R. W. Teel, Distribution and metabolism of ellagic acid in the mouse following intraperitoneal administration. Cancer Lett. 34, 165 ( 1987).
34. R. W. Teel and R. M. Martin, Disposition of the plant phenol ellagic acid in the mouse following oral administration by gavage. Xenobiotica 18, 883 (1988).
35. F. Delie, Evaluation of nano- and microparticle uptake by the gastrointestinal ttract. Adv. Drug Del. Rev. 34, 221 (1998).
36. N. Hussain, V. Jaitley, and A. T. Florence, Recent advances in the understanding of uptake of microparticulates across the gastrointestinal lymphatics. Adv. Drug Del. Rev. 50, 107 (2001).
37. V. Bhardwaj, S. Hariharan, I. Bala, A. Lamprecht, N. Kumar, R. Panchagnula, and M. N. V. R. Kumar, Pharmaceutical aspects of polymeric nanoparticles for oral delivery. J. Biomed. Nanotech. 1, 235 ( 2005).
38. G. Mittal, D. K. Sahana, V. Bhardwaj, and M. N. V. Ravi Kumar, Estradiol loaded PLGA nanoparticles for oral administration: Effect of polymer molecular weight and copolymer composition on release behavior in vitro and in vivo. J. Control. Rel. 119, 77 (2007).
39. 10 in rats. Free Radic. Biol. Med. 34, 563 (2003).
40. 10 on catalase activity and other antioxidant parameters in streptazocin induced diabetic rats. Biol. Trace Element Res. 109, 25 (2006).
41. C. S. Hii and S. L. Howell, Effects of epicatechin on rat islets of Langerhans. Diabetes 33, 296 (1984).